Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Calcium Dobesilate × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 38 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Burkitt Lymphoma 8 Recurrence 7 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasms, Plasma Cell 3 Leukemia, Biphenotypic, Acute 3 Neoplasms 2 Neoplasm Metastasis 2 Lymphoma, B-Cell 2 Lymphoma 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Smoldering Multiple Myeloma 1 Renal Insufficiency 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Plasmacytoma 1 Oropharyngeal Neoplasms 1 Neoplasm, Residual 1 Meningioma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphodepleting Chemotherapy 1 Leukemia, Myelomonocytic, Chronic 1 Immunoglobulin Light-chain Amyloidosis 1 Hodgkin Disease 1

Interventions

Cyclophosphamide 21 Rituximab 18 fludarabine 15 obinutuzumab 10 pirtobrutinib 9 fludarabine phosphate 9 venetoclax 8 ibrutinib 7 Prednisone 7 Lenalidomide 7 Biopsy 7 tocilizumab 6 glofitamab 6 Specimen Handling 6 Immunotherapy, Adoptive 6 polatuzumab vedotin 5 Mycophenolic Acid 5 Magnetic Resonance Spectroscopy 5 X-Rays 4 Tacrolimus 4 Phantoms, Imaging 4 Doxorubicin 4 pembrolizumab 3 palbociclib 3 olaparib 3 axicabtagene ciloleucel 3 Whole-Body Irradiation 3 Vincristine 3 Vemurafenib 3 Thiotepa 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡